Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

Yulan Chen, Jian‐Zi Lin, Ying‐Qian Mo, Jian‐Da Ma, Qianhua Li, Xiaoying Wang, Zehong Yang, Tao Yan, Dong-Hui Zheng, Lie DaiArthritis 2018 · DOI

TL;DR

This study investigates how Hepatitis B Virus (HBV) infection impacts the treatment outcomes for Rheumatoid Arthritis (RA) patients. It found that patients with chronic HBV infection (CHB) experience worse radiographic progression and slower clinical improvement when treated for RA, highlighting the need for careful monitoring of HBV reactivation during immunosuppressive therapy.

What Problem Does This Paper Address?

Rheumatoid Arthritis (RA) is a chronic autoimmune disease causing joint inflammation and destruction. While its exact causes are still being researched, infectious agents are suspected to play a role. Hepatitis B Virus (HBV) is a common global health burden that can affect various organs outside the liver, including joints. Previous research has hinted at a link between HBV and RA, with some studies suggesting HBV infection might even be more prevalent in RA patients. However, there was a lack of longitudinal studies examining how HBV infection specifically influences the effectiveness of RA treatments and disease progression in a real-world clinical setting. This paper aims to fill that gap by exploring the impact of chronic HBV infection on the therapeutic response and radiographic outcomes in RA patients undergoing standard treatment.

Methods

The researchers conducted a retrospective case-control study. They recruited 32 patients with RA and chronic HBV infection (CHB group) and matched them with 128 RA patients without HBV infection (non-CHB group) based on age, sex, and disease activity. Clinical data, including disease activity scores (DAS28-CRP), radiographic progression (measured by modified total Sharp score - mTSS), and treatment responses (ACR and EULAR criteria), were collected at baseline and over a 12-month follow-up period. They also monitored for HBV reactivation and liver function. Statistical analyses, including conditional logistic regression, were used to compare outcomes between the groups and identify risk factors for poor treatment response and radiographic progression.

Datasets

The study utilized clinical data from patients treated at Sun Yat-Sen Memorial Hospital between June 2012 and August 2016. The dataset comprised 32 patients with RA and chronic HBV infection and 128 age-, sex-, and disease activity-matched RA patients without HBV infection. No new benchmarks were introduced; the study relied on existing clinical and radiographic assessment tools.

Key Insights and Ideas

  • HBV as a "Driver" of RA Progression: The findings strongly suggest that chronic HBV infection isn't just a co-morbidity but actively contributes to worse outcomes in RA patients. It appears to act as a "driver factor" for disease progression.
  • Radiographic Damage is Accelerated: Patients with CHB showed significantly more joint damage progression over one year, indicating that HBV infection exacerbates the destructive nature of RA.
  • Treatment Efficacy is Hampered: The study revealed that CHB patients were less likely to achieve treatment targets and remission, and responded less favorably to standard RA therapies. This implies that the presence of HBV complicates treatment strategies.
  • HBV Reactivation is a Major Concern: A significant portion of CHB patients experienced HBV reactivation during immunosuppressive therapy, underscoring the critical need for vigilant monitoring and potentially prophylactic antiviral treatment.
  • Potential for a "Specific RA Phenotype": The results hint that RA patients with CHB might represent a distinct subgroup with unique treatment needs, possibly requiring adjusted regimens or routes of administration.

Key Results

  • Radiographic Progression: 53% of CHB patients experienced one-year radiographic progression compared to only 17% in the non-CHB group (p < 0.001).
  • Therapeutic Target Achievement: At 6 months, only 53% of CHB patients achieved the therapeutic target, versus 82% in the non-CHB group (p = 0.003). This difference persisted at 12 months.
  • Remission Rates: Similarly, remission rates at 6 months were lower in the CHB group (50% vs. 72%, p = 0.039).
  • ACR/EULAR Responses: CHB patients showed significantly lower rates of ACR20/50 responses and good/moderate EULAR responses, particularly at 6 and 12 months (all p < 0.05).
  • HBV Reactivation: A substantial 34% of CHB patients experienced HBV reactivation during the study, with two cases of hepatitis flare.
  • Risk Factors: CHB status was identified as an independent risk factor for both one-year radiographic progression (OR 2.403, p = 0.011) and failure to achieve therapeutic target within 6 months (OR 2.617, p = 0.023, in one model).

Limitations and Future Work

The authors acknowledge several limitations:

  • Real-world Observational Nature: The study was observational, meaning causality cannot be definitively proven. Patients were treated with varying medications, which could introduce confounding factors.
  • Baseline Bony Erosion: A high percentage of patients (over 70%) had pre-existing bony erosion at baseline, which is a known risk factor for progression. Future studies should include more patients with early RA without baseline erosion.
  • Small Sample Size: The relatively small number of RA patients with CHB (n=32) limits the robustness of the conclusions.

Future work suggested includes:

  • Larger, Multicenter Studies: To confirm these findings and explore the impact of HBV clearance on RA treatment response.
  • Investigating Specific Regimens: Further research is needed to understand how different RA treatment regimens, particularly those involving MTX and LEF, interact with HBV infection.
  • Clarifying HBV Clearance Impact: The effect of clearing HBV infection on RA outcomes remains an open question.

Summary updated

Abstract

HBV infection may play a deleterious role in radiographic and clinical outcomes in patients with RA, and HBV reactivation should be paid close attention during immunosuppressive therapy.
BibTeX
@inproceedings{chen2018deleterious,
  author = {Yulan Chen and Jian‐Zi Lin and Ying‐Qian Mo and Jian‐Da Ma and Qianhua Li and Xiaoying Wang and Zehong Yang and Tao Yan and Dong-Hui Zheng and Lie Dai},
  title = {{Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study}},
  booktitle = {Arthritis},
  year = {2018},
  doi = {10.1186/s13075-018-1548-5},
}
Figure